MAPK3 and non-small cell lung carcinoma: As shown in Figure 5, low expression of p-EGFR, p-ERK and Ki67 were found in wild-type EGFR NSCLC samples after co-treatment with theasinensin A and nimotuzumab, whereas the total protein levels of EGFR and ERK1/2 remained unchanged in each of the groups (Figure 5A–D).